Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/83338
Authors: 
Chalupka, Radovan
Year of Publication: 
2009
Series/Report no.: 
IES Working Paper 2/2009
Abstract: 
This paper analyses possible options how to improve the risk adjustment of the health insurance system in the Czech Republic. Out of possible options it argues for including Pharmaceutical Cost Groups (PCGs) as additional risk factors since it is an improvement that can be implemented almost instantaneously. On real data from an anonymous sickness fund it confirms that predictive performance of PCGs models is consistently better than the performance of the demographic model that is currently used. The study also describes and examines the Czech health insurance market and implications of proposed changes of the current government. Based on experience from other countries we point to a problem of risk selection if the changes are not accompanies by a tighter regulation, specifically in the form of improved risk adjustment formula.
Subjects: 
Risk adjustment
Managed competition
Health insurance
Pharmaceutical Cost Groups
Czech Republic
JEL: 
C10
D82
G22
I10
I11
I18
Document Type: 
Working Paper
Appears in Collections:

Files in This Item:
File
Size
443.04 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.